Kornimate/medical-research-clean huggingface dataset:
polidocanol sclerotherapy of pharynges for obstructive sleep apnea (osa) and snoring subjects(ss)

Conditions: Apnea; Snoring

Summary: the aim of this prospective study is to evaluate the results of polidocanol sclerotherapy of pharynx for osas \& ss,to reduce pharyngeal compliance.

polidocanol submucous sclerosis in the part of pharynges with 1% polidocanol injection.the injection should be in the retropharyngeal submucosa and lateral pharyngeal bands and lateral pharyngeal submucosa and in front submucosa of soft palate.the injection is multi-point,and each point injection is 0.3\~0.5ml;the total quantity/each time is not more than 5ml.every patient have to be treated about 1\~2 time.

Eligibility criteria:
inclusion criteria: * osas \& ss which palatopharyngeal collapse. exclusion criteria: * obstructive sleep apnea syndrome (osas) \& snoring subjects (ss),which anatomic narrow result in.

Keywords: sleep apnea,obstructive apnea-hypopnea index (ahi) polidocanol sclerotherapy pharynges
integrative group program for type 2 diabetes mellitus (t2dm)

Conditions: Diabetes Mellitus, Type 2

Summary: this is an open, randomized, controlled trial to determine the impact of an integrative group program on metabolic control and wellbeing perception of patients with t2dm. the integrative group program consists of 6 in-person sessions directed by a health coach and occurring every other week, and 6 asynchronous educative sessions during a period of 12 weeks.


Eligibility criteria:
inclusion criteria: * t2dm diagnosis of less than 5 years * age 18 to 80 years * current residence in nuevo león, méxico * availability to attend in-person sessions * provides written informed consent * able to read and write exclusion criteria: * currently under insulin treatment * t2dm diagnosis more than 5 years ago * comorbidities such as active cancer, acquired immunodeficiency (hiv+, aids), liver, cardiovascular, renal, pulmonary or thyroid disease. * history of severe neurologic or psychiatric disease (current or past diagnosis) * currently pregnant or intention of pregnancy in the following 3 months * males that consume more than 4 alcoholic beverages daily or 14 weekly * females that consume more than 3 alcoholic beverages daily or 7 weekly * consumption of any illicit drug

Keywords: integrative medicine diabetes mellitus type 2
vortioxetine in patients with depression and early dementia

Conditions: Major Depressive Disorder; Dementia

Summary: this study evaluates the effectiveness of vortioxetine on depressive symptoms in patients with depression and early dementia


Eligibility criteria:
inclusion criteria: * the patient has a primary diagnosis of recurrent major depressive disorder (mdd) with onset before age of 55, diagnosed according to dsm-5® * the current major depressive episode (mde) must be confirmed using the mini international neuropsychiatric interview (mini). * the patient has had the current mde for \<6 months. * the patient has a montgomery and åsberg depression rating scale (madrs) total score ≥26 at the baseline visit. * the diagnosis of onset of dementia has occurred at least 6 months prior to screening and after already being diagnosed with mdd. the diagnosis of dementia must be documented in patient's medical records. when deemed necessary per investigator judgement of patient clinical status and early dementia, the patient must be accompanied by a caregiver to study visits. * patients with dementia associated with vitamin b12 or folate deficiency should not be enrolled. * patients with or without treatment for dementia can be enrolled. for patients on treatment for dementia, there must be no change in treatment during the study and patients must be on stable dose for at least 3 months prior to the screening visit. * the patient has mini mental state examination (mmse) total score 20-24, inclusive. exclusion criteria: -the patient has any current psychiatric disorder or axis i disorder (dsm-5® criteria), established as the primary diagnosis, other than mdd, as assessed using the mini international neuropsychiatric interview (mini) or another diagnostic interview. other in- and exclusion criteria may apply
can we rely on hla to predict resistance to biological therapy in ibd patients

Conditions: Inflammatory Bowel Diseases

Summary: the investigators propose an observational study including patients with inflammatory bowel disease under biological therapy with anti-tnf, anti-integrin α₄β₇ or anti-interleukin 12-23 (ustekinumab), followed by an external gastroenterology consultation at centro hospitalar tondela-viseu.


Eligibility criteria:
inclusion criteria: * patients with the diagnosis of ibd (according to ecco diagnosis criteria); * adult patients (over 18 years); * full capability of signing informed consent. exclusion criteria: * patients who refuse to participate in the study; * patients submitted to prior biological therapy (only for the ibd-naive group)

Keywords: inflammatory bowel diseases hla biological therapy
a study to survey adults in south korea with cancer who receive padcev injection

Conditions: Urothelial Cancer

Summary: enfortumab vedotin (or padcev injection) is a treatment for cancer in the bladder lining (urothelial cancer). padcev injection is now available to treat this cancer. people in this study will be adults in south korea with locally advanced or metastatic urothelial cancer. metastatic means the cancer has spread to other parts of the body. during their care, the person's doctor will have prescribed padcev injection and other medicines to treat their cancer. people in the study will be treated according to their clinic's standard practice. this study is about collecting information only. this study will survey people who know they are receiving padcev injection. the aims of the study are to check outcomes of treatment with padcev and record any medical problems during the study. once a doctor has prescribed padcev injection, a person in the study will be observed for up to 48 weeks (about 1 year) after their first dose. during this time, a person's medical records will be reviewed to check for any medical problems and to follow the condition of their cancer. if a person in the study stops taking padcev injection sooner than 48 weeks, records will be reviewed until 30 days (1 month) after each person's last dose of padcev injection or until they start a different medicine for their cancer.


Eligibility criteria:
inclusion criteria: * patients who receive treatment with padcev injection, according to the approved local label. exclusion criteria: * patients with any contraindication for padcev injection, according to the approved local label. * patients who receive or are going to receive any investigational medicine during the observation period.

Keywords: urothelial cancer bladder cancer enfortumab vedotin padcev
evaluation of a cone-beam ct scanner for image guided radiotherapy

Conditions: Head and Neck Cancer; Lung Cancer; Breast Cancer; Abdominal Cancer; Pelvic Cancer

Summary: this is a feasibility study investigating the image quality of a new, high-performance cone beam ct (cbct) used for on-couch imaging during radiotherapy treatments.

this study will examine the image quality generated by a new cone-beam ct (cbct) imaging system integrated into an external beam radiation treatment delivery platform. normally, cbct images are acquired at the start of a daily radiation delivery treatment to align the patient with the images that were used to generate their radiation treatment plan. this alignment increases the precision of radiation delivery. this study will assess whether the improvements in image quality expected from the novel cbct imaging system are sufficient for the images to be used for more than just patient alignment. the study will enroll patients who will be treated with external beam radiation therapy for the following conditions: head and neck cancers, stage i lung cancer, stage ii to iv lung cancer, cancer in the left breast, tumors in the abdomen, and tumors in the pelvic region. each patient will undergo one additional imaging session with the novel cbct imaging system during which 1 or 2 cbct images will be acquired. the number of novel cbct images acquired depends on the location and type of the patient's tumor. the additional imaging session will occur on the same day as one of the patient's scheduled treatment delivery sessions to minimize impact on the patient's schedule. the patient's cancer treatment will not be affected by participation in this study. the methodology for the subject's treatment setup, ct simulation, treatment planning, image guidance and treatment delivery will be determined by the subject's treatment team. the images acquired by the novel cbct imaging system will be compared to standard cbct images acquired as part of the patient's treatment and to the ct simulation images used to define the patient's radiation treatment plan.

Eligibility criteria:
inclusion criteria: * the patient will be treated with external beam photon radiotherapy at maastro for head-and-neck cancer, stage i lung cancer, stage ii-iv lung cancer, left breast cancer, or tumours in the abdominal or pelvic region. * age ≥ 18 years * ability to understand the requirements of the study and to give written informed consent, as determined by the treating physician * provision of written informed consent exclusion criteria: * patient is pregnant
do power exercises result in superior benefits for people with patellofemoral pain?

Conditions: Patellofemoral Pain Syndrome

Summary: patellofemoral pain (pfp) is one of the most common forms of knee pain and has a negative impact on the level of physical activity and quality of life of patients. although strengthening of the hip and knee muscles has good clinical effects in the treatment of pfp, most exercise protocols do not follow the american college of sports medicine (acsm) guidelines and are not clearly described, making it difficult to apply them in practice clinical and research. in addition, recent studies have shown that these patients also have a power deficit of these muscles. however, it is not known whether the addition of power exercises to a muscle strengthening program would result in superior benefits, especially in relation to pain and physical function. therefore, the objective of this study is to verify if the improvement in pain intensity, physical function, kinesiophobia, self perception of improvement, quality of life and muscle function variables after a training program of strength and muscular power is superior to that observed in an isolated muscle strength training. this study will be randomized and controlled, developed with individuals with dpf, allocated in one of two groups: strength training group (stg) and strength and power training group (sptg). the primary outcomes will be intensity of pain and physical function, while the secondary outcomes will be kinesiophobia; self perception of improvement; quality of life; the peak of isometric abductor and hip extensor torque, and knee extensor; and the rate of development of torque of the abductors and extensors of hip, and extensors of knee at 30% and 90% of maximum isometric torque. participants in both groups will be evaluated before the intervention (pre), after the end of the intervention (post) and three, six and twelve months after the intervention. data analysis will follow the intention-to-treat principle. to compare the groups at different times (pre, post and after three, six and twelve months of the intervention) will be used two-way analysis of variance (group x moment) with mixed model, with bonferroni post hoc to identify specific differences. the significance level will be 0.05.


Eligibility criteria:
inclusion criteria: * men and women with bilateral or unilateral patellofemoral pain exclusion criteria: * history of knee surgery * history of hip or lumbar spine injury or pain * patellar instability * pain on palpation of the patellar tendon, iliotibial band, hoffa fat, goose paw tendons or knee joint line * signs or symptoms of meniscal or knee ligament injuries * presence of osgood-schlatter syndrome or sinding-larsen-johansson syndrome * any vestibular, neurological or musculoskeletal alterations that interfere or contraindicate the procedures of this study
intermittent portal and graft purge in living donor liver transplantation

Conditions: Hypotension; Ischemia Reperfusion Injury

Summary: post-reperfusion syndrome and ischemia-reperfusion insult are a common well-known complication in liver transplantation. several trials investigated variables that my contribute to the generation of these two complications for reducing their incidence and magnitude. the investigators will investigate the effect of acute conditioning of the recipients circulation to the vasoactive mediators in the graft as well as the congested intestine through intermittent purging of graft contents into the patient's systemic circulation in living donor liver transplantation.

patients are subjected to living donor liver transplantation. in this type of grafts, cold ischemia time is minimal and the graft contents of preservative solution are less than cadaveric grafts. the investigators in the current research use htc as a preservative solution. these factors justified the possibility of purging the graft and portal blood contents into the patient systemic circulation. the exposure to these fluids in this trial will be in an intermittent manner: the portal vein will be declamped for 5 seconds followed by 30 seconds of portal clamping. this will be repeated twice. the primary outcome objective in this trial will be the incidence of post-reperfusion syndrome. secondary objectives include the severity of prs, the incidence and severity of ischemia-reperfusion injury, graft and patient's survival.

Eligibility criteria:
inclusion criteria: * living donor liver transplantation recipients exclusion criteria: * non

Keywords: ischemia reperfusion post-reperfusion syndrome living donor liver transplantation patient outcome
vestibular pain interactions

Conditions: Healthy

Summary: the goal is to establish the practical usefulness of vestibular stimulation for modulating pain perception and to describe the possible mechanisms that could underlie neural vestibular-somatosensory interactions.


Eligibility criteria:
inclusion criteria: * weight: 50 - 100 kg * height: 155 - 185 cm * male subjects 18 years to 60 years of age * sufficient command of german language * written informed consent by the participant after information about the project * without any known history of neurological disease (especially motor, somatosensory disorders, peripheral neuropathies). * right-handedness exclusion criteria: 1. intellectually or mental impaired subjects 2. drug abuse 3. chronic alcohol consumption 4. no use of marihuana 24h before measurements. 5. no history of vestibular or auditory disorders. 6. diabetes mellitus 7. participants of other studies during study period and 30 days prior to study begin 8. any regular concomitant medication 9. abnormal qst parameters at the baseline measurement. 10. absent cheps-potentials at the baseline measurement.

Keywords: quantitative sensory testing contact heat evoked potentials vection stimulation 3d-turntable volunteers
a study of changes in bone mineral density as a function of consuming two different forms of calcium carbonate

Conditions: Osteopenia, Osteoporosis

Summary: the purpose of this study is to determine whether consuming calcium carbonate that has been micronized is more effective than the traditional form of calcium carbonate in maintaining or increasing bone mineral density in people who are currently taking bisphosphonates or other bone-health medications.

addressing the need for a form of supplemental calcium that could facilitate increases in bmd without the adverse effects often reported with limestone-based forms of calcium, a patented technology was developed to increase calcium absorbability using both zet mill/ball mill bottom-up pulverizing technology and 4d top-down ebonite charging technology to create a novel form of calcium referred to as micronized calcium carbonate (mcc). in comparison to other technologies that use water and high heat, which results in a loss of core nutrients and decreased product efficacy, the calcium produced by this unique pulverizing technology is micron-sized (0.03um - 10um) and therefore believed to be more effective. while its tiny size was thought to increase its absorption, the belief was that the intense activation of zinc via the patented ebonite charging process that could maximize the bioavailability of this calcium.

Eligibility criteria:
inclusion criteria: * must currently be under the care of a physician and taking prescription medication for bone health * must ensure with medical provider that there are no medical conditions that would preclude participation * must be able to swallow capsules * must be age 21 or above * must agree to follow study requirements as set forth in informed consent exclusion criteria: * men and women not currently taking prescription medication for bone health * conditions that inhibit gastrointestinal absorption of supplements * men and women less than 21 years of age * pregnant or breast feeding

Keywords: bone mineral density bone mineral content bone density bone health dual-energy x-ray absorptiometry
role of aromatase inhibitor to enhance ovulation in poor responder during induction with short antagonist protocol in cases of icsi

Conditions: Infertility Indicated for ICSI

Summary: study the effect of aromataze inhibitor induction together with short stimulation protocol by gonadotrphin releasing hormon antagonist in cases that expected to be poor responder before icsi

this is a prospective randomized case control study will be conducted in maternity hospital ivf unite minia university after being approved by local ethical committee of obstetrics and gynecology department faculty of medicine, all study details will be explained to patients and informed consent will be obtained before inclusion in the study . enrolled patients will be randomized into two groups using simple randomization by sealed opaque envelops contain serial computer generated numbers control group will receive hmg 300 iu daily start at first day of menses with follow up by trans vaginal ultrasound (tvus ) when at least three follicles reach 14mm diameter gnrh antagonist given 0.1 ml continue follow up when at least three follicles reach 17mm in diameter ovum pickup will done under tvus guide if less than three follicles cycle will be cancelled . study group will receive same management plus letrozole 2.5mg daily start at the first day of menses for 5 days and continue with same protocol

Eligibility criteria:
inclusion criteria: * infertlity indicated for icsi * ovarian factor * tubal factor * unexplained infertility * poor responders exclusion criteria: * expected high responder * endometriosis * male and uterine factors * ovarian mass or cyst

Keywords: aromataze inhibitor, poor responder ,induction
effect of metabolic syndrome on outcomes of transforaminal epidural steroid injection treatment in chronic lumbar radiculopathy

Conditions: Herniated Disk Lumbar; Metabolic Syndrome

Summary: transforaminal epidural steroid injection (tfesi) has been increasingly preferred in patients who can not benefit from conservative approach in the treatment of lumbosacral radiculopathic pain due to lumbar disc herniation. the aim of our study is to evaluate the effect of metabolic syndrome on the treatment results of transforaminal epidural steroid injection in patients with chronic radicular low back pain due to lumbar disc herniation.


Eligibility criteria:
inclusion criteria: * lumbar radiculopathy due to lumbar disc herniation, unresponsive to conservative treatments, duration of pain is less than 3 months, patients aged 18 to 65 years exclusion criteria: * the cases when fluoroscopy or epidural injection is contraindicated (coagulation disorders, pregnancy etc...), to have a history of lumbar spinal surgery, inflammatory diseases (rheumatoid arthritis, spondyloarthropathy), spinal infection or malignancy, systemic infection, spondylolisthesis or spinal stenoz at the involved or adjacent segments, allergies to local anesthetics, contrast dyes or steroids, refusal of a patient, history of prior lumbar spine surgery, presence of hip pathology (avascular necrosis, congenital hip dislocation etc...
dose response and safety study of topical methotrexate for the treatment of fingernail psoriasis

Conditions: Fingernail Psoriasis

Summary: the purpose of this clinical study is to compare the efficacy and safety of three concentrations of topical methotrexate for the treatment of fingernail psoriasis.

the purpose of this clinical study is to compare, in a controlled fashion, the response to three concentrations of methotrexate in novel topical formulations in the treatment of subjects with psoriasis of the fingernails. such a determination will be used as the basis for evidence of efficacy and safety of these formulations as a therapeutic treatment for fingernail psoriasis.

Eligibility criteria:
inclusion criteria: * diagnosed moderate fingernail psoriasis of at least two fingernails. * stable and unchanged psoriasis therapies for 2 months and must not have received methotrexate for 3 months prior to screening. * female patients who are not 5 years post menopausal or surgically sterile must use appropriate birth control for specified time periods and have negative pregnancy tests. exclusion criteria: * target or control fingernails that are thicker than 2mm, abnormal or infected (bacterial or fungal). * patients with immunosuppression, hiv, or neuropathies of the hand. * use of any methotrexate preparation, any topical anti-psoriatic medications or ultraviolet treatment within 2 months of study visit 1. * use of more that one 2-week course of oral corticosteroid therapy or one injection during 3 months prior to the screening visit. * use of manicures or cosmetic nail products during and within 7 days of the start of treatment. * use of any drug known to have potential for toxicity to a major organ during and within 90 days prior to the start of treatment. * patients who are nursing, pregnant or plan to become pregnant or father a child within the study time frame including within three months of the last dose of study medication.

Keywords: nail psoriasis psoriasis fingernail psoriasis methotrexate